|1.||Asaoka, Ai: 4 articles (04/2009 - 02/2004)|
|2.||Yamakawa, Minoru: 4 articles (04/2009 - 02/2004)|
|3.||Levite, Mia: 3 articles (04/2014 - 03/2005)|
|4.||Ganor, Yonatan: 3 articles (04/2014 - 03/2005)|
|5.||Yamada, Manabu: 3 articles (02/2006 - 02/2004)|
|6.||Hirota, Yoshikazu: 3 articles (02/2006 - 02/2004)|
|7.||Saido-Sakanaka, Hisako: 3 articles (02/2006 - 02/2004)|
|8.||Nakamura, Kikuyasu: 3 articles (02/2006 - 02/2004)|
|9.||Cohen, Ran: 2 articles (04/2014 - 02/2014)|
|10.||Teichberg, Vivian: 2 articles (04/2014 - 02/2014)|
|1.||Lyme Disease (Disease, Lyme)
|2.||Wounds and Injuries (Trauma)
04/01/2001 - "Recent results demonstrate that these peptides, such as peptide B, appear in invertebrates and vertebrates (including humans) immediately after tissue trauma, and maintain themselves for long durations (over 4h). "
03/29/2000 - "Titrations revealed the simultaneous appearance of Methionine-enkephalin (ME) and peptide B in invertebrates after stimulation by LPS (in a dose-dependent manner), surgical trauma or electrical stimulations to neural tissues of the mussel. "
10/01/2013 - "In this study, we evaluated the wound healing properties of tailored laminin-332 α3 chain (peptide A: PPFLMLLKGSTR) tethered to a type I collagen scaffold using mTGase by incorporating transglutaminase substrate peptide sequences containing either glutamine (peptide B: PPFLMLLKGSTREAQQIVM) or lysine (peptide C: PPFLMLLKGSTRKKKKG) in rat full-thickness wound model at two different time points (7 and 21 days). "
|3.||BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
07/15/2000 - "The engineered, chimeric peptide B-cell immunogen MVF-HER-2(628-647) may have applications in the prevention of HER-2-overexpressing cancers."
04/01/2009 - "Of these peptides, d-peptide B exhibited the highest selective cancer cell cytotoxicity against the mouse myeloma cell line, P3-X63-Ag8.653. "
06/01/2007 - "These results suggest the peptide B cell immunogen is appropriate as a vaccine for HER-2-overexpressing cancers because the resulting Abs show analogous biological properties to trastuzumab."
02/01/2004 - "The results of macroscopic and histopathologic examinations revealed that peptide B could protect the mice from infection. "
10/01/2005 - "Anti-bacterial activity of two synthesized oligopeptides, RLYLRIGRR-NH2 (peptide A) and RLRLRIGRR-NH2 (peptide B), both which based on a putative active site of defensin, an anti-bacterial peptide from the beetle Allomyrina dichotoma, was examined by macroscopic and histopathologic assessment during the course of infection in mice inoculated with methicillin-resistant Staphylococcus aureus (MRSA) in vivo. "
02/01/2004 - "Then, anti-bacterial activity of two newly synthesized peptides, RLYLRIGRR-NH(2) (peptide A) and RLRLRIGRR-NH(2) (peptide B) was also examined by macroscopic and histopathologic assessment during the course of infection in mice inoculated with antibiotic-resistant pathogenic Escherichia coli (E. "
12/01/2000 - "Chromatographic analysis of purified wild-type (wt) and mutant peptide B digested with a panel of specific proteases allowed us to identify the VP-2 residues Ser-2, Ser-6, and Ser-10 as the main phosphate acceptors for MVMp capsid during the natural viral infection. "
|2.||Collagen Type I (Type I Collagen)
|6.||A 17 (A-17)
|8.||Glutamate Receptors (Glutamate Receptor)
|9.||AMPA Receptors (AMPA Receptor)
|1.||Transplantation (Transplant Recipients)